Hologic readies mid-range 4500 scanner

Article

Like other bone densitometry vendors, Hologic is enjoying a banneryear, thanks to momentum created by Merck's Fosamax drug for thetreatment of osteoporosis. In addition to overall market growth,Hologic, of Waltham, MA, claims to have increased its market

Like other bone densitometry vendors, Hologic is enjoying a banneryear, thanks to momentum created by Merck's Fosamax drug for thetreatment of osteoporosis. In addition to overall market growth,Hologic, of Waltham, MA, claims to have increased its market sharein the segment to around 58%, compared with about 45% a year ago.

Hologic will try to build on its success by introducing a newmid-range member of its 4500 dual-energy x-ray absorptiometryfamily of bone measurement devices, according to Wade Fox, directorof marketing. Hologic developed the new system based on feedbackfrom clinicians, Fox said.

Hologic will also show its Sahara waterless ultrasound densitometer,which is not yet available in the U.S., as well as the mini C-armproduct line the company acquired through its purchase of Fluoroscanin August, Fox said.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.